Guggenheim Slaps Buy Rating on CRBP: $45 Target Signals Massive Upside
Corbus Pharmaceuticals gets Buy rating ($45 target). Drug CRB-701 shows strong cancer results, safer than rivals. Stock down 43% may be opportunity.
/ 79 items
#XY Analyst Up/Down↓
Craig-Hallum Initiates Strong Buy on Spruce Biosciences with $140 Price Target as TA-ERT Advances Toward Approval
Spruce Biosciences has a rare disease drug (TA-ERT) showing strong results, FDA path clear, big sales and upside potential.
Deutsche Bank and Truist Go Bullish on Ascentage Pharma
Ascentage Pharma gets Buy ratings; its cancer drugs show strong results, fast growth in China, and high future upside potential.
Oppenheimer Turns Bullish on Savara as Molgramostim Moves Closer to Approval
Savara gets FDA priority review for its drug, analyst raises target to $11, sees strong approval chances and upside.
JPMorgan Gives Hims & Hers a $35 Bullish Rating – Full GLP-1 Lineup Just Got Even Stronger
JPMorgan backs Hims & Hers Health as a strong buy, boosted by GLP-1 drugs and big deals with Novo Nordisk and Eli Lilly.
Mizuho Upgrades Outlook: Harmony’s Wakix Now Protected Until 2030
Harmony Biosciences wins key patent lawsuit, protecting Wakix from generics until ~2030; analyst stays positive with $50 target.